We have written an Editorial on paraquat intoxication (1), in which we review the physiopathology, the prognosis, and the treatment of this intoxication. One of the citations was that of Lin and colleagues, published last year in the AJRCCM (2). In this article spectacular results were obtained with respect to patient survival rates, given that some 82% of patients with moderate or severe intoxication survived after receiving, among other measures, pulse therapy with glucocorticoid and cyclophosphamide (CP). However, the dose of CP that appears in the mentioned article is much more toxic than the paraquat itself if we go by what is stated in the M ETHODS section, which says that patients received "15 g/kg of CP in 5% glucose saline 200 ml. . . intravenously infused for 2 h/d" for two days. In previous articles by the same group or by other authors doses of 1 g/day or of 15 mg/kg are used (3, 4). In addition, immunosuppressive therapy using high doses of CP do not usually use more than 7 g/m 2 of body surface (5) or 50 mg/kg/d (6). For these reasons, we believe that the dose of CP stated in the article must be a typographical error and should read milligrams (mg) instead of grams (g). However, until now this error seems not to have been noticed, or at least we have not seen it corrected in subsequent issues of your journal. We are firmly convinced that the treatment described by Lin will be used in many hospitals throughout the world and cited in textbooks of pneumology, critical care, clinical toxicology, emergency medicine, etc. Therefore, as well as informing Dr. Lin of our observation, we have thought it opportune that the readers of the AJRCCM also be informed on this important point, in order to avoid the possibility of treatment guidelines that could have severe consequences for patients suffering from paraquat intoxication. 
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From the Author :
We appreciated the comments from Dr. Antonio Duenas-Laita and his colleague (1). Initially, we used pulse therapy with cyclophosphamide (CP) in our previous work (2) . The dose of CP was 1 g/d for 2 d and methylprednisolone 1 g/d for 3 d in treating patients with moderate-to-severe paraquat (PQ) poisoning, and the results showed only 25% mortality rate in the pulse therapy group and 70.6% mortality in the control group (2). The dose was not the same as that used in Addo's study (3) , which used high dose of CP for 2 wk. We found 37.5% of pulse therapy group patients developed leukopenia (WBC Ͻ 3,000). In addition, all of them survived. This observation, similar to a previous report (3) , implies that CP-induced leukopenia may contribute to survival of PQ-poisoned patients. The mechanism is unknown and may result in partially reducing inflammation of PQ poisoning (4 
ATS GUIDELINES FOR METHACHOLINE AND EXERCISE CHALLENGE TESTING
To the Editor :
The Guidelines (1) are timely, useful, and well balanced. However, although they are in general evidence-based, the rationale of some recommendations remains unconvincing. (4) cannot be transferred, as proposed by the Guidelines, to the 5-breath challenge with methacholine. First, the difference between histamine and cholinergic responses may exceed one doubling dose either because of host differences (5, 6) or output differences across De Vilbiss 646 nebulizer (6, 7). Second, PD 20h is predictably higher than PD 20l , 1.5 times higher in normals and 1.15 higher in asthmatic subjects (2, 3) . Thus, contrary to the statement on p. 317 of the Guidelines (1), PC 20h and P C20l are not interchangeable for the very reason given on the same page: diagnostic methacholine challenge is carried out in patients with mild asthma and quasi-normal response to deep inhalation. Third, methacholine challenge with the rapid, 5-breath method may produce cumulative effects whereas histamine inhalation with the slower, tidal breathing method may not ([8] ; see also p. 317, first paragraph in Reference 1). 3. It is gratifying that the interest sparked by Reference 3 on Bayesian analysis is also shared by the Guidelines. However, the analysis of normative data is surprising. First, Fig. 3 (1) is based on three sets of (condensed?) normative data but only one is subsequently discussed and recommended. Second, I doubt that the patients that might benefit from methacholine challenge should be compared with a subset of "current asthma" (4). This small subset (17 subjects!) has 100% pre-test probability of asthma, way outside the recommended range of 30-70%, and 100% positive tests to methacholine. Some disease characteristics that may influence methacholine test results are not specified; e.g., length and severity of disease or treatment. Methacholine challenge is usually performed on oligosymptomatic patients, often with atypical triggers; they seem to respond to 2-8 mg/ml methacholine in only 5-14% of the cases (9). Moreover, it is inconsistent with Bayes' theorem to plot on the methacholine curve obtained from normals and the entire asthmatic population, the posttest probability resulting from a pretest probability of a subset of the latter population. The term of comparison for an asthmatic population is not the general population but the asthmatic population with similar asthma characteristics. Consequently, sensitivity, specificity, receiveroperator characteristics (8) and pretest probability should also be different. Finally, the Guidelines should have mentioned that the population used for normative data, age 20-29, (presumably) mostly white (4) is not representative for the entire population. 
From the Authors :
We thank Dr. Popa for his comments and apologize for overlooking his study supporting our recommendation to use the highest FEV 1 to calculate PC 20 (1) . Our rationale in choosing the largest FEV 1 was to avoid falsely low values from suboptimal tests. Although we believe we made the right choice, it may be less important than it appears. A recent retrospective comparison found PC 20 values to be almost identical using the highest and lowest FEV 1 in 225 methacholine challenges (2) . We understand the theoretical reasons why PC 20 values measured with different methodologies might not be comparable. Here again, a recent study confirms that quite different techniques produce nearly identical outcomes (3). We believe this clinical comparability is because the concentration of the challenge agent is more important than the cumulative dose.
Bennett and Davies did find dosimeter and tidal breathing methods gave different results when using the same DeVilbiss 646 nebulizer (4). However, they studied only 18 patients (who may have increased their use of inhaled corticosteroid during the study period) and reported the dosimeter technique was less reproducible than the tidal breathing technique (c.v. 54% versus 9.7%).
We acknowledge the superiority of using a clinical estimation of the pretest probability of asthma, modified by methacholine challenge results. The document clearly states that our Figure 3 was included only for illustration purposes and should not be used to calculate precise post-test probabilities in patients (5) . The pretest probability of asthma in any given patient is only a rough clinical estimate, and our intention was to give a qualitative illustration of how the MCT result could alter the pretest probability estimate. We look forward to research that will allow quantitative estimates of post-test probabilities.
Dr. Popa is right. We should have mentioned the population limitations of the normative data. Healthy elderly persons probably have lower PC 20 values compared with younger adults. We are not aware of studies demonstrating an effect of race, ethnicity, or country of origin on PC 20 in healthy persons. 
ENDOGENOUS AIRWAY ACIDIFICATION: IMPLICATIONS FOR ASTHMA PATHOLOGY
A recent article by Hunt and colleagues (1) reports that the pH of airway vapor condensates is relatively acidic in patients with acute asthma and returns to normal with treatment. They suggest that the pH of the exhaled vapor reflects the pH of the airway surfaces in these patients on the basis of comparisons made with undiluted tracheal secretions obtained in three patients. Although measurements of pH of exhaled vapor may prove useful, there are a number of aspects of the study that are of some concern. The investigators passed the exhaled air through a 0.3 m filter. The rationale for this approach is not explained, but it may have been used to remove saliva. However, if all droplets of any size were successfully removed from the exhaled air, then the samples could not contain any nonvolatile acids or buffers. The investigators collected the condensate in a cooled aluminum condensing conduit and then deaerated the samples with argon. Deaeration should have removed most of the volatile acids (e.g., CO 2 /H 2 CO 3 and NO/HNO 2 ). Fluid collected in this fashion should be nearly devoid of any acids or buffers and the pH would therefore be extremely difficult to measure accurately in the pH 5-8 range. Contact with any surface (e.g., the aluminum of the conduit or the plastic or glass in the collecting vials) could have a profound effect on the pH of the collected samples. Furthermore, the presence of NO in the exhaled air could have an effect on the interaction of the collected fluid and the aluminum of the conduit. It may prove very difficult to determine what the putative acids are in the exhaled fluid, and it seems unlikely that the acids or buffers in the collected fluid are representative of those on the airway surfaces. It would be instructive to compare the osmolality of the samples (presumably close to zero) with that of the airways (nearly isotonic).
It could be argued that the droplets trapped by the filter might provide a more accurate indication of the pH of the airways than water vapor. (Was the bathwater kept and the baby discarded?) Even if some droplets of the airway fluid do make their way past the filter, the constituents of these droplets would be significantly diluted by the collected water vapor. 
From the Authors :
We appreciate the thoughtful comments of Dr. Effros. Importantly, he suggests that water vapor may dilute particulate solutes in condensation assays. Particulates aerosolized from the airway wall may indeed seed vapor condensation. Thus, the degree of lower airway acidification in acute asthma may be greater than we have measured (1). Dr. Effros is correct that filtration prevents salivary contamination. Our system is designed (1, 2) to collect particles less than 0.3 m-lower airway particles that will not impact in the upper airway during exhalation (3). He is also correct that particles-not just vapor-clearly came through the filter: the condensate contained M concentrations of solutes such as nitrite (NO 2 Ϫ ) and nitrate (1, 2) . In this regard, water particles may be less than 0.01 m diameter (3), and boiled acids (pH 4-5) condensed through our system have little change in pH. We and others are investigating what does and does not go through filters of various sizes during condensate collection. However, lower airway particles are clearly of more immediate interest than salivawhich does not come through in our system-when it comes to studying asthma biology.
Dr. Effros correctly points out that deaeration removes CO 2 ; this was our objective. With the acidic CO 2 removed, the pH is remarkably stable over time and is reproducible on repeated studies of the same subject (coefficient of variation 3.3% [1] ). Nitric oxide (NO) loss is trivial. It evolves rapidly
